139 related articles for article (PubMed ID: 27460949)
1. Effect of saracatinib on pulmonary metastases from hepatocellular carcinoma.
Xiong J; Wu JS; Mao SS; Yu XN; Huang XX
Oncol Rep; 2016 Sep; 36(3):1483-90. PubMed ID: 27460949
[TBL] [Abstract][Full Text] [Related]
2. Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma.
Tsang CM; Cheung KC; Cheung YC; Man K; Lui VW; Tsao SW; Feng Y
Biochim Biophys Acta; 2015 Mar; 1852(3):541-51. PubMed ID: 25496992
[TBL] [Abstract][Full Text] [Related]
3. Capn4 contributes to tumour growth and metastasis of hepatocellular carcinoma by activation of the FAK-Src signalling pathways.
Dai Z; Zhou SL; Zhou ZJ; Bai DS; Xu XY; Fu XT; Chen Q; Zhao YM; Zhu K; Yu L; Yang GH; Wang Z; Wu WZ; Zhou J; Fan J
J Pathol; 2014 Nov; 234(3):316-28. PubMed ID: 24962955
[TBL] [Abstract][Full Text] [Related]
4. 3'3-Diindolylmethane inhibits migration, invasion and metastasis of hepatocellular carcinoma by suppressing FAK signaling.
Li WX; Chen LP; Sun MY; Li JT; Liu HZ; Zhu W
Oncotarget; 2015 Sep; 6(27):23776-92. PubMed ID: 26068982
[TBL] [Abstract][Full Text] [Related]
5. ASPP2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the Src/FAK/Snail axis in hepatocellular carcinoma.
Xu L; Tong X; Zhang S; Yin F; Li X; Wei H; Li C; Guo Y; Zhao J
Tumour Biol; 2016 Oct; 37(10):13669-13677. PubMed ID: 27473084
[TBL] [Abstract][Full Text] [Related]
6. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma.
Liao X; Song G; Xu Z; Bu Y; Chang F; Jia F; Xiao X; Ren X; Zhang M; Jia Q
BMC Cancer; 2020 Jan; 20(1):31. PubMed ID: 31931755
[TBL] [Abstract][Full Text] [Related]
8. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.
El Sayed I; Helmy MW; El-Abhar HS
Life Sci; 2018 Nov; 213():248-257. PubMed ID: 30292831
[TBL] [Abstract][Full Text] [Related]
10. Rheum palmatum extract exerts anti-hepatocellular carcinoma effects by inhibiting signal transducer and activator of transcription 3 signaling.
Tan ZB; Fan HJ; Wu YT; Xie LP; Bi YM; Xu HL; Chen HM; Li J; Liu B; Zhou YC
J Ethnopharmacol; 2019 Mar; 232():62-72. PubMed ID: 30553869
[TBL] [Abstract][Full Text] [Related]
11. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY
Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210
[TBL] [Abstract][Full Text] [Related]
12. Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.
Dong M; Rice L; Lepler S; Pampo C; Siemann DW
Anticancer Res; 2010 Nov; 30(11):4405-13. PubMed ID: 21115886
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
Cavalloni G; Peraldo-Neia C; Sarotto I; Gammaitoni L; Migliardi G; Soster M; Marchiò S; Aglietta M; Leone F
Mol Cancer Ther; 2012 Jul; 11(7):1528-38. PubMed ID: 22452946
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Hingorani P; Zhang W; Gorlick R; Kolb EA
Clin Cancer Res; 2009 May; 15(10):3416-22. PubMed ID: 19447875
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.
Chua KN; Kong LR; Sim WJ; Ng HC; Ong WR; Thiery JP; Huynh H; Goh BC
Oncotarget; 2015 Oct; 6(30):29991-30005. PubMed ID: 26358373
[TBL] [Abstract][Full Text] [Related]
18. Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.
Yang J; Cai X; Lu W; Hu C; Xu X; Yu Q; Cao P
Cancer Lett; 2013 Jan; 328(2):243-51. PubMed ID: 23032719
[TBL] [Abstract][Full Text] [Related]
19. COL4A1 promotes the growth and metastasis of hepatocellular carcinoma cells by activating FAK-Src signaling.
Wang T; Jin H; Hu J; Li X; Ruan H; Xu H; Wei L; Dong W; Teng F; Gu J; Qin W; Luo X; Hao Y
J Exp Clin Cancer Res; 2020 Aug; 39(1):148. PubMed ID: 32746865
[TBL] [Abstract][Full Text] [Related]
20. PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
Fang H; Jin J; Huang D; Yang F; Guan X
Cancer Sci; 2018 Jun; 109(6):1949-1957. PubMed ID: 29601121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
